Treatment of prostatic cancer with slow-release formulation of luteinizing hormone releasing hormone (LH-RH) analog |
| |
Authors: | H Fuse S Akimoto K Akakura J Shimazaki S Murakami |
| |
Institution: | Department of Urology, School of Medicine, Chiba University. |
| |
Abstract: | A slow-release formulation of the luteinizing hormone releasing hormone (LH-RH)analog(TAP-144-SR) was administered in 6 cases of prostatic cancer. Five were untreated cases, 3 of moderately-differentiated and 2 of poorly-differentiated cancers (four D2 and one C, NX), the other (D2) was under control by another LH-RH analog. The plasma level of luteinizing hormone and follicle stimulating hormone fell below normal, and the plasma testosterone was less than 1 ng/ml by four weeks after start of treatment. According to the National Prostatic Cancer Project Criteria, 2 of the untreated cases showed a partial response and 3 of the untreated ones showed a stable response, one of which underwent transurethral resection later. The pretreated case still continued controlled more than 4 months. No side effect was noticed. |
| |
Keywords: | |
|
|